Neuphoria Therapeutics Rises 2.4% as It Pursues Scancell Merger – Market Outlook
Neuphoria Therapeutics sees a 2.42% rise as it plans a merger with Scancell, offering investors a chance to benefit from a strategic biopharma partnership.
- NEUPHORIA THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read